Table 1. Characteristics of studies included in the current meta-analysis (n=20).
| Authors | Published year | Journal | Year enrolled | Country | Study design | Stage | Population | Follow-up (mo) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RRH | LRH | RRH* | LRH* | |||||||
| Magrina et al. [14] | 2008 | Gynecol Oncol | 2003–2006 | USA | Prospective | IA2–IB2 | 27 | 31 | 31.1 | 31.1 |
| Nezhat et al. [15] | 2008 | JSLS | 2000–2008 | USA | Prospective | IA2–IIA | 13 | 30 | 12 | 29 |
| Estape et al. [16] | 2009 | Gynecol Oncol | 2006–2008 | USA | Prospective | IA2–IB2 | 32 | 17 | 7.8 | 31.4 |
| Lambaudie et al. [17] | 2010 | Eur J Surg Oncol | 2007–Unknown | France | Retrospective | IA2–IVA | 22 | 16 | 11.6 | 19.5 |
| Tinelli et al. [18] | 2011 | Ann Surg Oncol | 2003–2010 | Italy | Retrospective | IA1–IIA | 23 | 76 | 24.5 | 46.5 |
| Gortchev et al. [19] | 2012 | Gynecol Surg | 2006–2010 | Bulgaria | Retrospective | IB1 | 73 | 46 | 10.5 | 51.1 |
| Chen et al. [20] | 2014 | Int J Gynecol Cancer | Unknown | Taiwan | Retrospective | IA–IIB | 24 | 32 | 13.9 | 34.6 |
| Kim et al. [21] | 2014 | Int J Gynecol Cancer | 2008–2013 | ROK | Matched | IB1–IIA1 | 23 | 69 | UK | UK |
| Yim et al. [22] | 2014 | Yonsei Med J | 2009–2013 | ROK | Retrospective | IA1–IIA2 | 60 | 42 | 25 | 19.5 |
| Corrado et al. [23] | 2016 | Int J Gynecol Cancer | 2010–2013 | Italy | Prospective | IB2–IIB | 41 | 41 | 30 | 60.1 |
| Mendivil et al. [24] | 2016 | Surg Oncol | 2009–2013 | USA | Retrospective | IA2–IIB | 58 | 49 | 39 | 39 |
| Nie et al. [25] | 2017 | Int J Gynecol Cancer | 2009–2016 | China | Retrospective | IA2–IIA2 | 100 | 833 | UK | UK |
| Pellegrino et al. [26] | 2017 | Acta Biomed | 2010–2016 | Italy | Retrospective | IA2–IIA1 | 34 | 18 | 59 | 30 |
| Heo et al. [27] | 2018 | Obstet Gynecol Sci | 2009–2013 | ROK | Retrospective | IA1–IIB | 19 | 22 | UK | UK |
| Luo et al. [28] | 2018 | BMC Womens Health | 2014–2015 | China | Prospective | IA–IIB | 30 | 30 | UK | UK |
| Gallotta et al. [29] | 2018 | Eur J Surg Oncol | 2010–2016 | Italy | Matched | IA2–IIB | 70 | 140 | 24 | 36 |
| Corrado et al. [30] | 2018 | Int J Gynecol Cancer | 2001–2016 | Italy | Retrospective | IB1 | 88 | 152 | 46.6 | 41.7 |
| Chong et al. [31] | 2018 | Int J Gynecol Cancer | 2008–2013 | ROK | Retrospective | IB1–IIA2 | 65 | 60 | 60 | 72 |
| Ind et al. [32] | 2019 | Int J Med Robot | 2010–2017 | Unknown | Prospective | IB1 | 32 | 25 | UK | UK |
| Chen et al. [33] | 2019 | World J Clin Cases | 2014 | China | Retrospective | IA1–IIB | 216 | 342 | 29 | 30 |
LRH, laparoscopic radical hysterectomy; ROK, republic of Korea; RRH, robotic radical hysterectomy.
*Median or mean.